Neoadjuvant Chemotherapy Beneficial in High-Risk UTUC
Findings of a phase 2 trial support the use of neoadjuvant chemotherapy as a standard of care, according to investigators.
All articles by John Schieszer, MA
Intensified ADT for Recurrent High-Risk Prostate Cancer Beneficial
Intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 52 weeks prolonged PSA progression-free survival compared with ADT alone among men with high-risk biochemically recurrent prostate cancer following radical prostatectomy.
Warning Issued About Online Tracking Technology
In a recent bulletin, the federal Office for Civil Rights suggests steps that practices can take to protect patient data.
Men With Prostate Cancer Live Longer if Relatives Had It
A family history of prostate cancer appears to boost awareness of the disease, which in turn prompts men to seek screening, according to investigators.
Amazon’s Virtual Health Clinic Raises Patient Privacy Issues
How the retail giant will use the sensitive medical data it collects is among the concerns.
Medical Practices Face Widespread Staff Shortages
Physician retirements and challenges in recruiting and retaining staff are among the reasons medical practices are struggling with staff shortages.
Picking the Best Place to Practice Medicine
Annual pay, growth potential, cost of living are among the important considerations.
Prostate Cancer Consensus Conference Offers Guide to Clinical Dilemmas
An international panel weighed in on management controversies in intermediate- and high-risk and locally advanced prostate cancer.
Sophisticated Cybercrime Group Targeting Health Care Providers
The FBI and other federal agencies have issued warnings about a ransomware and data extortion group called the Daixin Team.
Dialysis Initiation Is Followed by Stabilization of Symptom Number, Burden
Study findings could help inform older patients who opt to start dialysis on what to expect regarding development of their symptom burden, according to investigators.
- Loading...
Loading...
Next post in End-Stage Renal Disease
Loading... 
Loading...